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Abstract A novel heat-stable nterotoxin (ST) designated as 
Y-STc was purified to homogeneity from the culture supernatant 
of a pathogenic strain of Yersinia enterocolitica serotype 03  and 
its amino acid sequence was determined. The mature Y-STc was 
found to consist of 53 amino acid residues, which includes the 
putative pro-sequence. The molecular weight of Y-STc was 5638 
and constituted the largest molecular size in the family of cur- 
rently known STs. The minimum effective dose of purified Y-STc 
in the suckling mouse assay was 0.6 ng (0.1 pmol), indicating that, 
despite the long sequence, Y-STc is the most toxic in the ST 
family. 
Key words: Heat-stable nterotoxin; Amino acid sequence; 
Purification; Pro sequence; Yersinia enterocolitica 
1. Introduction 
Heat-stable nterotoxins (STs) are peptide toxins produced 
by bacterial enteropathogens such as enterotoxigenic Esche- 
richia coli [1,2], Yersinia enterocolitica [3-5] and Vibrio cholerae 
[6-8], and are responsible for acute diarrhea in humans. ST 
binds to a membrane-bound guanylate cyclase which serve as 
a specific cell surface receptor for ST, followed by elevation of 
the intracellular cGMP level [9-11]. 
Y. enterocolitica is a Gram-negative bacillus frequently asso- 
ciated with human gastrointestinal disorders [12,13]. It is well 
known that pathogenic strains of Y. enterocolitica produce an 
ST named Y-ST, which is thought o be involved in the viru- 
lence of the organism [14-17]. In addit ion to the known Y-ST, 
the existence of novel enterotoxins produced by Y. entero- 
colitica was documented by demonstrat ing that strains which 
failed to hybridize with a probe for the gene encoding Y-ST still 
possessed enterotoxic activity [18]. Based on the reactivity with 
monoclonal  antibodies against known STs, the novel Y-STs 
were classified in to two types. We designated the classical Y-ST 
as Y-STa and the novel STs as Y-STb and Y-STc. Quite re- 
cently, we reported the amino acid sequence of Y-STb [5]. In 
this paper, we describe the purification and structure of the 
novel Y-STc produced by a clinical isolate of Y. enterocolitica 
03.  Interestingly, despite having the largest molecular size in 
the ST family, Y-STc possessed the highest oxic activity. 
*Corresponding author. Fax: (81) (3) 3411-7308. 
2. Experimental 
2.1. Bacterial strain and culture conditions 
A clinical strain (86-11) of Y. enterocolitica belonging to the serotype 
03 isolated from a patient in Japan was kindly provided by Dr. T. 
Maruyama, The National Institute of Public Health, Japan. The strain 
was cultured as previously described [19]. 
2.2. Purification of Y-STc 
The culture supernatant of Y. enterocolitica strain 86-11 was fraction- 
ated by ammonium sulfate precipitation (80% saturation). After centrif- 
ugation (15,000 x g, 30 min, 4°C), the resulting pellets were resolved in 
buffer A (0.1 M NaC1, 10 mM Tris-HC1, pH 7.2) and dialyzed against 
buffer A. The dialyzate was applied to a DEAE-Sephacel column 
(2 × 26 cm) equilibrated with buffer A. The column was washed with 
500 ml of buffer A and eluted with a linear gradient from 0.1 to 0.5 M 
NaC1 in a total volume of 500 ml, at a flow rate of 20 ml/h. An aliquot 
of each fraction was tested for enterotoxicity in the suckling mouse. The 
active fractions were concentrated, ialyzed against buffer B (0.3 M 
NaCI, 10 mM Tris-HC1, pH 7.2), and then subjected to gel-filtration 
on a Sephacryl S-100 HR column (2 x 92 cm) equilibrated with buffer 
B. The elution was performed using buffer B at a flow rate of 10 ml/h. 
The toxic fractions were purified further by reverse-phase high-per- 
formance liquid chromatography (RP-HPLC). The HPLC instrument 
used in this study was a high-pressure gradient system which consisted 
of two Waters model 510 HPLC Pumps. The absorbance of the eluent 
was monitored at 214 and 280 nm, using Waters Absorbance Detectors 
model 440 and 441, respectively. The following elution programs were 
used for the purification of Y-STc. Program I, column: CAPCELL 
PAK C18 SG120 (4.6 x 250 mm); elution: linear gradient of 10-35% 
acetonitrile (1%/min) in 10 mM ammonium acetate (pH 5.7), flow rate: 
1.0 ml/min. Program II, column: YMC R-ODS-5 (4.6 x 250 mm); elu- 
tion: linear gradient of 1545% acetonitrile (l%/min) in 0.1% tri- 
fluoroacetic acid (TFA); flow rate: 1.0 ml/min. Program III: column: 
Develosil ODS-T-5 (4.6 x 150 mm); elution: linear gradient of 10M0% 
acetonitrile (l%/min) in 10 mM ammonium acetate (pH 5.7); flow rate: 
1.0 ml/min. Program IV: column: Develosil ODS-T-5 (4.6 x 150 mm); 
elution: linear gradient of 5-50% acetonitrile (l%/min) in 0.1% TFA; 
flow rate: 1.0 ml/min. 
2.3. Suckling mouse assay 
Toxic activity was assayed in the suckling mouse as previously de- 
scribed [20]. The fluid accumulation (FA) ratio was calculated as the 
ratio of the weight of the entire intestines of the suckling mouse to that 
of the rest of the body. An FA ratio of over 0.09 was considered to 
indicate a positive response. The minimum effective dose (MED) was 
the minimum amount (weight or mole) of toxin giving the positive 
response. The amount (mole) of Y-STc was calculated from the data 
from amino acid analysis of the acid hydrolysate. 
2.4. Sequence determination 
The purified toxins were digested with endoproteinase Asp-N in 100 
mM sodium phosphate buffer (pH 7.9) for 7 h at 37°C as described 
previously [5]. The digests were separated by RP-HPLC on a Develosil 
ODS-T-5 column (4.6 × 150 mm) with a linear gradient of 2-50% ace- 
tonitrile (1%/min) in 0.1% TFA, at a flow rate of 1.0 ml/min. The amino 
acid sequences of the resulting peptide fragments were determined by 
automated Edman degradation using an ABI 437A gas-phase protein 
sequencer or fast atom bombardment tandem mass spectrometry 
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(FAB-MS/MS) using a JEOL JMS-HX/HX110A four-sector tandem 
mass pectrometer as previously described [21,22]. The C-terminal frag- 
ments were identified by the procedure of Rose et al. with some modi- 
fications [5,21,23]. Electrospray ionization mass spectrometry (ESI- 
MS) and amino acid analysis were carried out as previously described 
[5]. 
3. Results and discussion 
3.1. Isolation of Y-STc 
The culture supernatant of strain 86-11 was partially purified 
by ammonium sulfate precipitation, DEAE-Sephacel ion-ex- 
change chromatography, Sephacryl S-100 HR gel-filtration and 
RP-HPLC (Program I), as described in section 2. The toxic 
fractions obtained by RP-HPLC using Program I were sepa- 
rated further by RP-HPLC using Program II to yield two active 
peaks, as shown in Fig. 1. Each peak fraction was individually 
rechromatographed using Program Ill and then further puri- 
fied by using Program IV. Two different toxic peptides (T-1 and 
T-2) were purified from the respective active fractions. 
3.2. Sequence determination of Y-STc 
ESI-MS showed that the molecular weights of purified toxins 
were 5638 (T-I) and 5621 (T-2). On the basis of the observed 
molecular weights and the data from amino acid analysis, the 
amino acid compositions ofthe purified toxins were determined 
as shown in Table 1, indicating that both of the toxins consist 
of about 50 amino acid residues. Although the deduced amino 
acid compositions of T-1 and T-2 were nearly identical, their 
observed mass values were different. The mass difference of 17 
atomic mass units strongly suggested that the N-termini of T-1 
and T-2 are Gln and 5-oxo-2-pyrrolidinecarboxylic acid (pyro- 
glutamic acid: pGlu) residues, respectively, and the remaining 
sequences are identical. 
The primary structures of purified T-1 and T-2 were estab- 
lished, as shown in Fig. 2, by determination f the amino acid 
sequences of their endoproteinase Asp-N fragments. As esti- 
mated using the data from ESI-MS and amino acid analysis, 
the amino acid sequences of T-1 and T-2 were identical except 
for their N-termini which were Gin in T-1 and pGlu in T-2. 
Thus, we concluded that T-1 is the original Y-STc and that T-2 
is a product where the N-terminal Gin residue of T-1 is con- 
verted into pGlu during the biosynthesis orpurification. It was 
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Fig. l. The second RP-HPLC profile in the purification of Y-STc. The 
toxic fractions obtained by the first RP-HPLC were applied to a YMC 
R-ODS-5 column. The separation was carried out with a different 
solvent system (Program II) from the first RP-HPLC using Program 
I. See text for the details of chromatographic conditions. 
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Fig. 2. Separation of the endoproteinase Asp-N digest of purified Y- 
STc (T-I). See text for chromatographic conditions. The amino acid 
sequences ofthe numbered fragments were determined by automated 
Edman degradation rFAB-MS/MS as shown in the upper panel. The 
N-terminal mino acid residue of fragment 3 was pGlu and the remain- 
ing sequence was identical to that of fragment 1. It appears that the 
N-terminal Gin residue of fragment 1was converted into pGlu during 
the digestion. Based on these data, the amino acid sequence ofY-STc 
(T-I) was established as shown. The N-terminal sequence was con- 
firmed by automated Edman degradation of intact T-1. Following 
separation of the endoproteinase Asp-N digest of T-2, fragments 2 8 
were found. 
demonstrated that the six Cys residues in the C-terminal por- 
tion formed three intramolecular disulfide linkages, by FAB- 
MS of the intact and reduced C-terminal fragments [5,22]. 
FAB-MS of fragment 6 showed that a component with a molec- 
ular weight of 134 linked to Cys 25 via a disulfide bond. Al- 
though the chemical structure of this component is still unclear, 
the same modification has been observed in Cys 3 of Y-STa [3]. 
The molecular weight calculated from the determined structure 
is 5638, which is in good agreement with the molecular weight 
estimated by ESI-MS. 
STs produced by ~arious enteropathogenic bacteria share a 
highly conserved sequence: 
C-C-[E/D]-[L/I/V]-C-C-N-P-A :C-[A/T/F]-G-C 
This sequence constitutes the minimal structure ssential for 
toxicity and has been designated as the 'toxic domain' or the 
'core sequence' [24]. In Y-STc, the toxic domain is also con- 
served in its C-terminal portion. 
The structural gene of Y-STa encodes a polypeptide with 71 
amino acid residues composed of three regions (Fig. 3) [14]. The 
mature Y-STc purified from the culture supernatant consisted 
of 53 amino acid residues, which is similar to the length of the 
pro-form of Y-STa (Fig. 3). The length of the secreted mature 
polypeptides ranges from only 17 amino acid residues for 
NAG-ST and O1-ST produced by E cholerae [6,8] to 30 amino 
acid residues for Y-STa and Y-STb produced by Y. entero- 
colitica [3,5]. To our knowledge, Y-STc has the largest molecu- 
lar size in the ST family. The alignment of the amino acid 
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Y-STc: 
Y-STa: 
10 
QETASGQVGDVSSST I A 
I I I  I I I  I I I 
MKK I VFVLVLMLSSFGAFGQETVSGOFSDALSTP  D T 
20 30 40 S0 
Y-STc T EVS EAECGTQSATTQGENDWDWCCE LCCN PAC FGC 
I t  t I I I I  I I  I I  I111  I I 
Y-STa: AF. .VYKQACDPPSPPAEVSSDWD CCDVCCNPACAGC 
Y-STb: KACDTQTPS PS EEND DWCCEVCCNPACAGC 
Fig. 3. Alignment of the amino acid sequences of the mature Y-STc, the precursor protein of Y-STa and the mature Y-STb. The precursor protein 
of Y-STa is composed of three regions which are the pre-sequence of 19 amino acid residues (in italics) corresponding to a signal peptide, the 
pro-sequence of 22 amino acid residues (in outline) and the mature Y-STa of 30 amino acid residues (in plain letters) [14]. The 26 identical residues 
between the mature Y-STc and the putative pro-form of Y-STa are indicated by vertical lines. The C-terminal part (23-53) of Y-STc and the mature 
Y-STb share 19 amino acid residues (61% homology). 
sequences of Y-STc and the pro-form of Y-STa revealed that 
there is a sequence similarity of 49% (26 residues/53 residues) 
(Fig. 3). Some investigators have examined and discussed the 
role of the pro-sequence of ST in maturation [25-29]. In the 
present study, it was shown that the long polypeptide consisting 
of 53 amino acid residues, including the putative pro-sequence, 
is secreted as the mature toxin with a highly potent enterotox- 
icity. This implies that the proteolytic processing of a putative 
intermediate composed of the pro and mature regions appear- 
ing in the periplasm is not essential for the secretion of the 
mature toxin from the periplasmic space to the extracellular 
space through the outer membrane, and supports the model 
proposed by Guzm~n-Verduzco and Kupersztoch [26,27]. 
3.3. Toxicity o f  Y-STc 
The purified Y-STc (T-l) showed a MED of 0.6 ng (0.1 pmol) 
in the suckling mouse assay (Fig. 4). This indicates that Y-STc 
is 4-fold more potent than Y-STb (MED: 1.2 ng, 0.4 pmol) [5] 
and E. coli STh (MED: 0.8 ng, 0.4 pmol) [30], which have been 
known as the most toxic STs. The MED of T-2 was nearly 
identical to that of T-l, indicating that the conversion of N- 
terminal Gln to pGlu does not affect the enterotoxic activity. 
In ST molecules produced by V. cholerae O1, the molecules 
with the shorter N-terminal sequences howed more potent 
toxicities, and the MED of the largest one with 28 amino acid 
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Fig. 4. Determination of the MED of Y-STc in the suckling mouse 
assay. The MED was determined as the minimum amount of toxin 
giving an FA ratio of more than 0.09. By linear regression analysis 
(r = 0.95, y = 1.964 + 0.144x) of the data, the MED (in mole) of Y-STc 
(T-l) was determined to be 0.1 pmol, which corresponded to 0.6 ng, 
residues was ten times more than that of the smallest one with 
17 amino acid residues [8]. In contrast, Y-STc was the most 
toxic in the ST family despite having the longest sequence. ST 
molecules in which Glu and Leu residues take the positions of 
acidic and aliphatic amino acid residues between two -Cys-Cys- 
sequences in the toxic domain, respectively, are known to pos- 
sess high toxicity [31]. It has been reported that a Trp residue 
at a position just preceding the toxic domain functions to en- 
hance the toxicity, as shown in Y-STb (Fig. 3) [5]. The highest 
enterotoxicity of Y-STc could be ascribed to a synergism of 
both the above properties which are present in Y-STc. 
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Table 1 
Amino acid compositions and observed mass values of the two entero- 
toxins (T-1 and T-2) purified from culture supernatant of Y. entero- 
colitica 86-11 
T-1 T-2 
Asp 4.69 (5) 4.78 (5) 
Thr 5.67 (6) 5.66 (6) 
Ser 4.46 (6) 5.19 (6) 
Glu 9.69 (10) 9.69 (10) 
Pro 1.16 (1) 1.08 (1) 
Gly 4.98 (5) 5.23 (5) 
Ala 5.00 (5) 5.00 (5) 
l/2Cys ND (7) ND (7) 
Val 2.60 (3) 3.04 (3) 
Ile 1.15 (1) 1.04 (1) 
Leu 1.30 (1) 1.14 (1) 
Phe 1.26 (1) 1.25 (1) 
Yrp ND (2) ND (2) 
Total (53) (53) 
ESI-MS 5638 5621 
The amino acid composition is shown as a normalized value with 
alanine representing five residues. The numbers in parentheses refer to 
the number of residues in the peptide found by sequencing, l/2Cys, 
half-cystine; ND, not determined. 
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